Advertisement
Singapore markets close in 22 minutes
  • Straits Times Index

    3,296.33
    -7.67 (-0.23%)
     
  • Nikkei

    38,633.02
    +62.26 (+0.16%)
     
  • Hang Seng

    18,335.32
    -95.07 (-0.52%)
     
  • FTSE 100

    8,217.98
    +12.87 (+0.16%)
     
  • Bitcoin USD

    65,726.95
    +531.06 (+0.81%)
     
  • CMC Crypto 200

    1,369.39
    -13.27 (-0.96%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • Dow

    38,834.86
    +56.76 (+0.15%)
     
  • Nasdaq

    17,862.23
    +5.21 (+0.03%)
     
  • Gold

    2,347.30
    +0.40 (+0.02%)
     
  • Crude Oil

    81.32
    -0.25 (-0.31%)
     
  • 10-Yr Bond

    4.2170
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,591.68
    -8.11 (-0.51%)
     
  • Jakarta Composite Index

    6,810.46
    +83.55 (+1.24%)
     
  • PSE Index

    6,344.56
    -21.47 (-0.34%)
     

Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?

Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?

Most pharma investors are familiar with power players like Eli Lilly (NYSE: LLY) and Bristol Myers Squibb, (NYSE: BMY) and both businesses have a lot to offer passive income investors too. As one of the world's most preeminent pharma conglomerates, Eli Lilly and its portfolio of products covers all sorts of illnesses, including Alzheimer's disease, diabetes, and different cancers. It also has 21 programs in phase 3 clinical trials, and another 21 in phase 2 trials.